Switch theme
Sign up to access all valuation multiples
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
2006
96
Last FY Revenue n/a
LTM EBITDA -$141M
-$30.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Olema Pharmaceuticals has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$141M.
In the most recent fiscal year, Olema Pharmaceuticals achieved revenue of n/a and an EBITDA of -$142M.
Olema Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Olema Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$141M | XXX | -$142M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$146M | XXX | -$142M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$134M | XXX | -$129M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Olema Pharmaceuticals's stock price is $5.
Olema Pharmaceuticals has current market cap of $361M, and EV of -$30.3M.
See Olema Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$30.3M | $361M | XXX | XXX | XXX | XXX | $-2.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Olema Pharmaceuticals has market cap of $361M and EV of -$30.3M.
Olema Pharmaceuticals's trades at n/a EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Olema Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Olema Pharmaceuticals has a P/E ratio of -2.7x.
See valuation multiples for Olema Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $361M | XXX | $361M | XXX | XXX | XXX |
| EV (current) | -$30.3M | XXX | -$30.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -2.8x | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOlema Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Olema Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Olema Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Olema Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Olema Pharmaceuticals acquired XXX companies to date.
Last acquisition by Olema Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Olema Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Olema Pharmaceuticals founded? | Olema Pharmaceuticals was founded in 2006. |
| Where is Olema Pharmaceuticals headquartered? | Olema Pharmaceuticals is headquartered in United States of America. |
| How many employees does Olema Pharmaceuticals have? | As of today, Olema Pharmaceuticals has 96 employees. |
| Who is the CEO of Olema Pharmaceuticals? | Olema Pharmaceuticals's CEO is Dr. Sean P. Bohen, M.D.,PhD. |
| Is Olema Pharmaceuticals publicy listed? | Yes, Olema Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Olema Pharmaceuticals? | Olema Pharmaceuticals trades under OLMA ticker. |
| When did Olema Pharmaceuticals go public? | Olema Pharmaceuticals went public in 2020. |
| Who are competitors of Olema Pharmaceuticals? | Similar companies to Olema Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Olema Pharmaceuticals? | Olema Pharmaceuticals's current market cap is $361M |
| Is Olema Pharmaceuticals profitable? | Yes, Olema Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Olema Pharmaceuticals? | Olema Pharmaceuticals's last 12 months EBITDA is -$141M. |
| What is the current EV/EBITDA multiple of Olema Pharmaceuticals? | Current EBITDA multiple of Olema Pharmaceuticals is 0.2x. |
| What is the current FCF of Olema Pharmaceuticals? | Olema Pharmaceuticals's last 12 months FCF is -$90.8M. |
| What is the current EV/FCF multiple of Olema Pharmaceuticals? | Current FCF multiple of Olema Pharmaceuticals is 0.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
